Is the FDA protecting the public from harmful drugs?

Article Abstract:

Sandra Kweder, Deputy Director of U.S. Food and Drug Administration (FDA), debates with David Graham, Associate Director of U.S. FDA, on whether the FDA is protecting the public from harmful drugs. Kweder believes that FDA created a strong post-market drug-safety program designed to assess adverse events while Graham feels that whenever a serious safety issue arises post-marketing, FDA's immediate reaction is almost one of denial, rejection and heat.

Management dynamics, Executive changes & profiles, Management, Officials and employees, Beliefs, opinions and attitudes, Company business management, United States. Food and Drug Administration, Kweder, Sandra, Graham, David Duane

---

Access to information

Article Abstract:

Drug Safety Oversight Board will establish a new Drug Watch Web Page on the Internet, which will provide the public with emerging information about safety, issues that may alter the risk or benefit analysis of a drug. One-page information will also be provided for all drugs, offering basic information and safety updates in a consumer-friendly format.

On-Line Information Services, Videotex & Teletext, Services information, Services, Online services, Online information services, Company systems management, Information management, Information services, Online information service

---

Similar abstracts:

• Abstracts: The issues. Going to court. Changing society
• Abstracts: The Politics of Energy. Hydrogen Initiative. The issues

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.